Backed by a $202 million fundraiser, biotech Aimmune has announced plans to file its potential peanut allergy treatment at the end of the year following a phase 3 trial success.
A new social media campaign called #ThinkHand aims to challenge perceptions about what is important for multiple sclerosis patients - and also bring about changes in drug trials.
Artificial Intelligence company BenevolentAI has bought a drug discovery and development facility at the Babraham Research Campus in Cambridge for an undisclosed sum.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
